Repatha clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Repatha Clinical Trials: Efficacy and Safety in High-Risk Cholesterol Patients
LDL-C Lowering Efficacy in Clinical Trials
Repatha (evolocumab) is a PCSK9 inhibitor that has been tested in multiple phase III clinical trials for its ability to lower low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia, including those with familial hypercholesterolemia and atherosclerotic cardiovascular disease. Across these trials, Repatha consistently demonstrated significant reductions in LDL-C levels, ranging from approximately 54% to 77% compared to placebo in patients with clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia, and about 30% in those with homozygous familial hypercholesterolemia 457. These effects were observed both as an add-on to statin therapy and as monotherapy in statin-intolerant patients 57.
Cardiovascular Outcomes and Event Reduction
The FOURIER trial and its extension, FOURIER-OLE, showed that Repatha not only lowers LDL-C but also significantly reduces the incidence of major cardiovascular adverse events by 15% in patients with atherosclerotic cardiovascular disease who have residual hypercholesterolemia despite statin therapy . The reduction in clinical events was closely linked to the degree of LDL-C lowering, even at very low LDL-C concentrations .
Safety and Tolerability Profile
Clinical trials have shown that Repatha is generally well tolerated, with a safety profile similar to placebo or other lipid-lowering agents. The most common side effects reported were nasopharyngitis, upper respiratory tract infection, flu, back pain, and injection-site reactions such as redness, pain, or bruising. Allergic reactions, including rash and hives, have also been observed, but serious adverse events were rare 457. Importantly, studies found no negative impact on cognitive function .
Use in High-Risk and Difficult-to-Treat Populations
Repatha is particularly valuable for patients who are unable to reach LDL-C targets with statins alone or who are statin-intolerant. It is approved for use in adults with heterozygous or homozygous familial hypercholesterolemia and those with clinical atherosclerotic cardiovascular disease requiring additional LDL-C lowering 1245+1 MORE. Real-world and clinical trial data presented at major cardiology congresses continue to support its efficacy and safety in these high-risk groups .
Dosing and Administration
Repatha is administered as a subcutaneous injection, either 140 mg every two weeks or 420 mg once a month. For adults with homozygous familial hypercholesterolemia, the recommended dose is 420 mg monthly 457.
Conclusion
Clinical trials have established Repatha as a highly effective and well-tolerated option for lowering LDL-C and reducing cardiovascular risk in patients with hyperlipidemia, especially those who are high-risk or unable to achieve target cholesterol levels with standard therapies. Its safety profile and ability to prevent major cardiovascular events make it a key adjunctive therapy in modern lipid management 1456+1 MORE.
Sources and full results
Most relevant research papers on this topic